884 related articles for article (PubMed ID: 29945808)
21. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation.
Zhao Y; Lu Y; Qin Y
Int J Cardiol; 2018 Nov; 270():167-171. PubMed ID: 29903520
[TBL] [Abstract][Full Text] [Related]
22. Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review.
Gerfer S; Djordjevic I; Eghbalzadeh K; Mader N; Wahlers T; Kuhn E
Ther Adv Cardiovasc Dis; 2022; 16():17539447221093963. PubMed ID: 35481366
[TBL] [Abstract][Full Text] [Related]
23. Periprocedural Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation Without Discontinuation of a Vitamin K Antagonist and Direct Oral Anticoagulants.
Kojima T; Fujiu K; Fukuma N; Matsunaga H; Oshima T; Matsuda J; Matsubara T; Shimizu Y; Oguri G; Hasumi E; Morita H; Komuro I
Circ J; 2018 May; 82(6):1552-1557. PubMed ID: 29657252
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience of uninterrupted oral anticoagulants during atrial fibrillation ablation in elderly patients: a comparison with non-elderly patients.
Matsunaga-Lee Y; Egami Y; Yanagawa K; Nakamura H; Matsuhiro Y; Yasumoto K; Tsuda M; Okamoto N; Tanaka A; Yano M; Yamato M; Shutta R; Sakata Y; Nishino M; Tanouchi J
Heart Vessels; 2020 Oct; 35(10):1454-1462. PubMed ID: 32335715
[TBL] [Abstract][Full Text] [Related]
25. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
[TBL] [Abstract][Full Text] [Related]
26. Catheter ablation in adult congenital heart disease on uninterrupted oral anticoagulation: Is it safe? Data from a large single-center study.
Foerschner L; Kriesmair J; Telishevska M; Kottmaier M; Bourier F; Reents T; Lengauer S; Lennerz C; Krafft H; Maurer S; Popa M; Kolb C; Deisenhofer I; Hessling G
Heart Rhythm; 2022 Apr; 19(4):648-655. PubMed ID: 34958942
[TBL] [Abstract][Full Text] [Related]
27. Intermittent anticoagulation guided by continuous atrial fibrillation burden monitoring using dual-chamber pacemakers and implantable cardioverter-defibrillators: Results from the Tailored Anticoagulation for Non-Continuous Atrial Fibrillation (TACTIC-AF) pilot study.
Waks JW; Passman RS; Matos J; Reynolds M; Thosani A; Mela T; Pederson D; Glotzer TV; Zimetbaum P
Heart Rhythm; 2018 Nov; 15(11):1601-1607. PubMed ID: 29981863
[TBL] [Abstract][Full Text] [Related]
28. Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.
Kanaoka K; Nishida T; Iwanaga Y; Nakai M; Tonegawa-Kuji R; Nishioka Y; Myojin T; Okada K; Noda T; Kusano K; Miyamoto Y; Saito Y; Imamura T
Eur Heart J; 2024 Feb; 45(7):522-534. PubMed ID: 38117227
[TBL] [Abstract][Full Text] [Related]
29. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.
Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G
Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
Ukaigwe A; Shrestha P; Karmacharya P; Hussain SK; Samii S; Gonzalez MD; Wolbrette D; Naccarrelli GV
J Interv Card Electrophysiol; 2017 Mar; 48(2):223-233. PubMed ID: 27771820
[TBL] [Abstract][Full Text] [Related]
31. Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives.
Briceño DF; Madan N; Romero J; Londoño A; Villablanca PA; Natale A; Di Biase L
Expert Opin Drug Saf; 2017 Jul; 16(7):769-777. PubMed ID: 28475380
[TBL] [Abstract][Full Text] [Related]
32. Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry.
Kornej J; Kosiuk J; Hindricks G; Arya A; Sommer P; Rolf S; Husser D; Lip GY; Bollmann A
Clin Res Cardiol; 2015 Jul; 104(7):603-10. PubMed ID: 25707763
[TBL] [Abstract][Full Text] [Related]
33. Thromboembolism and Mortality in the Tasmanian Atrial Fibrillation Study.
Admassie E; Chalmers L; Bereznicki LR
J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):329-336. PubMed ID: 29642709
[TBL] [Abstract][Full Text] [Related]
34. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
[TBL] [Abstract][Full Text] [Related]
35. "As Needed" nonvitamin K antagonist oral anticoagulants for infrequent atrial fibrillation episodes following atrial fibrillation ablation guided by diligent pulse monitoring: A feasibility study.
Zado ES; Pammer M; Parham T; Lin D; Frankel DS; Dixit S; Marchlinski FE
J Cardiovasc Electrophysiol; 2019 May; 30(5):631-638. PubMed ID: 30706975
[TBL] [Abstract][Full Text] [Related]
36. Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score ≤3: a long-term outcome study.
Saad EB; d'Avila A; Costa IP; Aryana A; Slater C; Costa RE; Inácio LA; Maldonado P; Neto DM; Camiletti A; Camanho LE; Polanczyk CA
Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):615-21. PubMed ID: 21841192
[TBL] [Abstract][Full Text] [Related]
37. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
[TBL] [Abstract][Full Text] [Related]
38. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence.
Martin AC; Godier A; Narayanan K; Smadja DM; Marijon E
Circulation; 2018 Aug; 138(6):627-633. PubMed ID: 30354610
[TBL] [Abstract][Full Text] [Related]
39. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.
Santarpia G; De Rosa S; Polimeni A; Giampà S; Micieli M; Curcio A; Indolfi C
PLoS One; 2015; 10(5):e0126512. PubMed ID: 25974377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
